Developments in pharmacotherapy for the preservation of ovarian function during cancer treatment

Basit Öğe Kaydı
dc.authorid0000-0003-2287-799X
dc.authorid0000-0003-0914-7757
dc.contributor.authorTuran, Volkan
dc.contributor.authorOktay, Kutluk
dc.date.accessioned2025-05-02T07:07:04Z
dc.date.available2025-05-02T07:07:04Z
dc.date.issued2025
dc.departmentFakülteler, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Kadın Hastalıkları ve Doğum Ana Bilim Dalı
dc.description.abstractIntroduction: Cancer is one of the major causes of human death, and anti-cancer therapy often results in premature ovarian failure and infertility, depending on factors such as age, initial ovarian reserve, and chemotherapy type and dose. Fertility preservation procedures, such as oocyte, embryo, and ovarian cortex cryopreservation, can help women achieve pregnancy after cancer treatment. However, the development of pharmacological therapies to protect ovarian function during chemotherapy would represent a significant advancement. Areas covered: We searched the published articles in PubMed up to December 2024, containing key words '"chemotherapy",' 'cancer,' '"ovarian protection",' '"pharmacological therapy",' '"ovarian reserve"' and '"fertility".' Chemotherapeutic agents act via various mechanisms in the human ovary, including direct DNA damage leading to oocyte apoptosis, as well as damage to ovarian stroma and microvascular architecture. In recent years, numerous protective agents have emerged, showing promise in protecting ovaries from chemotherapy-induced damage. However, most studies have relied on animal models, and only a limited number have directly tested these agents in human ovarian tissue. At present, no pharmacological treatment has been conclusively proven effective for preserving fertility. Expert opinion: A comprehensive understanding of the mechanisms underlying chemotherapy-induced ovarian damage is critical for the development of efficient and targeted pharmacological therapies.
dc.description.sponsorshipThis work was supported by the National Institutes of Health (NICHD RO1HD053112).
dc.identifier.citationTuran, V., & Oktay, K. (2025). Developments in pharmacotherapy for the preservation of ovarian function during cancer treatment. Expert Opinion on Pharmacotherapy, https://doi.org/10.1080/14656566.2025.2495090
dc.identifier.doi10.1080/14656566.2025.2495090
dc.identifier.issn1465-6566
dc.identifier.issn1744-7666
dc.identifier.pmid40271805
dc.identifier.urihttps://doi.org/10.1080/14656566.2025.2495090
dc.identifier.urihttps://hdl.handle.net/20.500.13055/967
dc.identifier.wosqualityQ3
dc.indekslendigikaynakPubMed
dc.indekslendigikaynak.otherSCI-E - Science Citation Index Expanded
dc.institutionauthorTuran, Volkan
dc.institutionauthorid0000-0003-2287-799X
dc.language.isoen
dc.publisherTaylor & Francis
dc.relation.ispartofExpert Opinion on Pharmacotherapy
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectCancer
dc.subjectChemotherapy
dc.subjectFertility Preservation
dc.subjectOvarian Protection
dc.subjectPharmacological Therapies
dc.titleDevelopments in pharmacotherapy for the preservation of ovarian function during cancer treatment
dc.typeArticle
dspace.entity.typePublication

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
Kapalı Erişim
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Cerrahi Tıp Bilimleri Bölümü Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu